Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Biological Psychiatry|November 7, 2019
The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for PsychosisG Paul Amminger, Barnaby Nelson, Connie Markulev, et al.
Frontiers in Psychiatry|June 30, 2020
Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical TrialMaximus Berger, Barnaby Nelson, Connie Markulev, et al.
Journal of Affective Disorders|August 10, 2021
Primary prevention of depression: An umbrella review of controlled interventionsGonzalo Salazar de Pablo, Marco Solmi, Julio Vaquerizo-Serrano, et al.
Schizophrenia Bulletin Open|August 15, 2024
Distress Related to Attenuated Psychotic Symptoms: Static and Dynamic Association With Transition to Psychosis, Nonremission, and Transdiagnostic Symptomatology in Clinical High-Risk Patients in an International Intervention TrialBarnaby Nelson, Hok Pan Yuen, G Paul Amminger, et al.
Frontiers in Psychiatry|June 28, 2019
Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical TrialMaximus Berger, Barnaby Nelson, Connie Markulev, et al.
Schizophrenia Research|December 19, 2018
Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trialLuke K Bolt, G Paul Amminger, John Farhall, et al.
Early Intervention in Psychiatry|September 7, 2020
Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosisAlison McLaverty, Kelly A Allott, Maximus Berger, et al.
Bjpsych Open|September 8, 2022
Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trialNicholas Cheng, Alison McLaverty, Barnaby Nelson, et al.
Brain, Behavior, and Immunity|October 8, 2021
The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trialSubash Raj Susai, David Mongan, Colm Healy, et al.
Behaviour Research and Therapy|December 3, 2019
Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trialJessica A Hartmann, Stefanie J Schmidt, Patrick D McGorry, et al.
Pageof 9